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Tissue  factor is an  integral  membrane  glycoprotein 
that serves as an essential  cofactor  for  the  blood  coag- 
uIation  factor  VIIa.  Recent  studies  have  attempted  to 
localize the tissue factor recognition determinant of 
human  factor  VIIa.  While several regions of factor VIIa 
have been implicated as important for tissue factor 
binding,  the  high affinity tissue  factor  recognition  de- 
terminant of  human factor VIIa is unknown. In order 
to define  the  determinant, we constructed  a set of six 
chimeric  proteins  composed  of  portions of factor VI1 
and  factor  IX. We then  utilized  the  chimeras  in  com- 
petition  experiments with ‘261-labeled  factor VIIa for 
recombinant tissue factor bound to an Immobilon-P 
membrane. The data indicate that the high affinity 
tissue factor  recognition  determinant  of human factor 
VIIa is within  the  epidermal  growth  factor  domains. 
Factor VI1 is a vitamin K-dependent glycoprotein that plays 
a critical role in  the early stages of blood coagulation. Within 
the vasculature, factor VI1 circulates as a zymogen serine 
protease. Conversion of factor VI1 to  its activated form, factor 
VIIa, is achieved  by proteolytic cleavage at a single site within 
the zymogen VII, resulting in a two-chain serine protease 
composed of an (NHp-terminal) light chain of  20 kDa and a 
heavy chain of 30 kDa connected by a single disulfide bond. 
The light chain is composed of a series of domains. The NH2- 
terminal domain is the y-carboxyglutamic acid (Gla)’ domain 
that is believed to confer phospholipid binding capabilities to 
the protein (1). Following the Gla domain are  an aromatic 
stack domain and two epidermal growth factor (EGF1 and 
-2)-like domains which prior to  this report had no demonstra- 
ble function. The serine protease activity is conferred by the 
trypsin-like heavy chain. 
Tissue factor (TF) is an integral membrane glycoprotein 
that is expressed in a variety of tissues where it serves as a 
cofactor for factor VI1 and VIIa. Factor VIIa possesses little 
or no catalytic activity in  the absence of tissue factor and 
Ca2+ ions. When factor VIIa is complexed with tissue  factor 
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apoprotein, Ca2+ ions, and phospholipid, an -57,000-fold in- 
crease in  catalytic efficiency is observed when compared with 
the identical complex minus tissue factor (2). The interaction 
of factor VI1 with tissue factor has been explored by kinetic 
analysis (2)  and by direct binding experiments (3-8). These 
studies established that factors VI1 and VIIa bind to tissue 
factor with comparable affinities. The  VII(a)/TF dissociation 
constants vary with experimental conditions and range from 
0.08 nM to 13 nM. Previous work has also established a factor 
VII/tissue factor stoichiometry of 1:l and suggests that tissue 
factor exists as a dimer on  the cellular surface (3). Recent 
studies suggest that the Gla domain and a 12-amino acid 
segment of the heavy chain are important in factor VII(a) 
binding to tissue factor (6-8). 
In  an effort to definitively delineate the tissue factor rec- 
ognition determinant on factor  VII(a), we prepared a series 
of chimeric proteins composed of regions of factors VI1 and 
IX. We then evaluated these factor VII/IX chimeras for their 
ability to interact with human  tissue  factor apoprotein. The 
data  in  this report suggest that  the high affinity tissue factor 
recognition determinant of human factor VII(a) resides within 
the factor VI1 EGF domains and that the factor VI1 Gla 
domain and heavy chain do not directly participate in the 
high affinity binding to tissue factor. 
EXPERIMENTAL PROCEDURES 
Materials 
Immobilon-P transfer membrane was purchased from Millipore. 
The Minifold I dot blot apparatus was purchased from Schleicher & 
Schuell. Nonfat dry milk is a product of the Carnation Co. Tissue 
factor apoprotein was a generous gift of Genentech, Inc. T-4 DNA 
ligase, restriction endonucleases, polynucleotide kinase, and Sequen- 
ase were purchased from U. s. Biochemical Corp. Calf intestine 
alkaline phosphatase was purchased from Boehringer Mannheim. 
Monoclonal antibodies A7,  A5, and A1  were previously described (9, 
10).  The monoclonal antibody FxC008  was a gift from S. Paul Bajaj 
and has also been previously described (10, 11). The two monoclonal 
antibodies to factor VII, one Ca2+-dependent (CDVII) and  the other 
Ca2+-independent (CIVII), were gifts from Dr. U. Hedner (Novo 
Nordisk, Copenhagen) and Dr. Walter Kisiel (University of New 
Mexico School of Medicine, Albuquerque). Oligonucleotides were 
purchased from Oligos Etc. Affiprep and Affi-Gel 10 were obtained 
from Bio-Rad, IODO-BEADS from Pierce Chemical Co., and Gene- 
ticin (G418) from Gibco/BRL. Human factor IX was purchased from 
Enzyme Research Laboratories. Iz6I-Protein A, N a T ,  and [a-35S] 
dATP were purchased from Amersham Corp. Vitamin K (Aquame- 
phyton) was purchased from Merck Sharp  and Dohme.  Gla analysis 
was generously provided by Dr. Paul Friedman of Merck Sharp  and 
Dohme (West Point, PA). 
Methods 
Cloning of the Factor VZZ cDNA-The factor VI1 cDNA  was cloned 
by utilizing the polymerase chain reaction (PCR) (12). The complete 
nucleotide coding sequence of factor VI1 was assembled from five 
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factor VI1 fragments generated by PCR. The fragments were ampli- 
fied from both  a  human liver cDNA preparation and from human 
genomic  DNA. The oligonucleotides used to prime the amplification 
were designed  by evaluating the previously published factor VI1 amino 
acid and nucleotide sequence (13,141 with the DNA analysis program 
of Little and Mount (15). The program back-translates an amino acid 
sequence into its ambiguous DNA sequence and  then identifies en- 
donuclease sites that can be introduced into  the nucleotide sequence 
without changing the amino acid sequence. This facilitated the design 
of factor VI1 oligonucleotide primers that possess unique endonucle- 
ase  sites  (Table I, A). Consequently, this allowed the five factor VI1 
PCR fragments to ultimately be connected into  the full-length factor 
VI1 coding sequence. This full-length cDNA was then sequenced 
completely by the dideoxy chain  termination method (16). In addition 
to  the unique restriction sites, oligo 7-1, which represents the 5’ end 
of the cDNA, also contains  a Kozak sequence (GCCACC) (17) prior 
to  the  start  site ATG. 
Creation of the Chimeric cDNAs-In order to create the six chi- 
meric cDNAs, compatible restriction  sites were introduced into  the 
cDNAs of factor VI1 and IX. The restriction  sites were introduced at  
points within the cDNAs that correspond to portions of the two 
proteins that are identical. The modified cDNAs were then digested 
with the appropriate sets of restriction endonucleases. The various 
cDNA fragments that comprise the chimeric constructions were then 
purified, assembled into the complete chimeric cDNAs, and se- 
quenced. The restriction  sites were incorporated into  the cDNAs of 
factors VI1 and IX  either by site-directed mutagenesis (18, 19) or in 
some instances during the PCR amplification as in the case of factor 
VI1  cDNA. The factor IX cDNA was available in our laboratory and 
had already been partially modified to include two restriction  sites at 
appropriate places within the cDNA (20). The design of the oligomers 
for mutagenesis was again guided by the program of Little and Mount 
(15) (Table I, B). A general representation of the chimeric protein 
constructions is shown in Fig. 1. 
Expression and Purification of Recombinant Proteins-The factor 
VII, factor IX, and chimeric cDNAs were cloned into  the mammalian 
expression vector pCMV5 (21). Each one of the eight expression 
constructs was then cotransfected (22) with pSV2-neo (23) into the 
human kidney cell line 293 (ATCC CRL 1573). Cells were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM) (high glucose) sup- 
plemented with L-glutamine, penicillin, streptomycin, and 10% fetal 
calf serum. Stable transformants were selected with the antibiotic 
G418. Resistant colonies were subcloned and  the culture media as- 
sayed for recombinant protein expression by immunoradiometric 
assay (20). The monoclonal antibodies used in these analyses (de- 
scribed above) were used in various combinations depending upon 
which recombinant protein was being detected. The colonies with the 
highest levels of recombinant protein expression were selected for 
expansion. The  transformants were expanded and transferred to 850- 
cm2 roller bottles for larger scale protein production. The expression 
medium was composed of DMEM/F-12 (high glucose) containing 1- 
1.5% fetal calf serum and 2 pg/ml vitamin K. The medium  (175 ml/ 
bottle) was harvested every 2 days and filtered through a 0.45-pm 
Durapore filter (Millipore) and  then frozen at  -70 “C. After several 
liters were collected from each  transformant, the medium  was thawed 
and  the CaC12 concentration adjusted to 20 mM. The medium was 
applied directly to a column containing one of the Ca2+-dependent 
(conformation-specific) monoclonal antibodies (A7 or CDVII) cou- 
pled to either Affiprep 10 or Affi-Gel 10 (-2-5 mg/ml) The column 
was washed initially with 20 mM Tris-Cl, pH 7.2,  0.05% Tween 20, 
100 mM NaCI, 20 mM CaCI2. This was followed by a second wash 
with 20 mM Tris-C1, pH 7.2, 1.0 M NaCl, 20 mM CaC12. The proteins 
were eluted from the column with 20 mM Tris-C1, pH 7.2, 100 mM 
NaC1, 20 mM EDTA and were then concentrated with a microcon- 
centrator Centricon 30 (Amicon). The protein concentration was 
determined by utilizing the Bio-Rad  protein assay kit. 
SDS-Polyacrylamide Gel Electrophoresis and Western  Blot  Anuly- 
sis-SDS-polyacrylamide gel electrophoresis (PAGE) and Western 
TABLE I 
Oligonucleotides  used in the polymerase chain reaction (PCR) and mutagenesis 
A, oligomers used in the PCR amplification of fragments of the human factor VI1 cDNA. The underlined 
nucleotide sequence corresponds to  the respective restriction sites. Boldface nucleotides correspond to  the Kozak 
sequence. The five fragments were subsequently connected into  the full-length factor VI1 coding sequence. Fragment 
1 lacks the 66 base pairs that correspond to  the alternatively spliced exon 2, resulting in  a 38-amino acid prepro 
leader. B, oligomers used in the mutagenesis of the factor VI1 and IX cDNAs. 
A 
Fragment 5’ oligo 3’ oligo Sequence Restriction DNA site template 




7-2 CCGGAATTCGCACACTGGTCACCATCACTGTAA- BsteII 
GAAATCC 






3 7-5 CCATGCGGCCGCATACCTATTCTAGAAAAAAGA Not 1 
CTGCCATGGACACTCCCCTTTGGG Ncol 
Exon 7 
4 7-7 TGTCCATGGCAGGTCCTGTTGTTGGTGAATGGAG Nco 1 Exon 8 
AvaI 






Oligomer  Sequence Template cDNA VI1 IX Result of mutagenesis 
Mute 1 GACTTCACTCGAGTTGTTGGTGG X 
Mute 2 GCAAACCCCAAGCTCCGAGTTGTGGGGGGC X 
Created XhoI sites; used in 
LC/VII HC 
the creation of the IX 
Mute 3 ATGCCAGCAAGCCCCAAGGGCGAATTGTGGG X 
GCACCCAATCATTTAAGCCCCAAGGGCGGATTGTTGGTGGAGAAG X 
Created BglI sites; used in 
the creation of the VI1 
LC/IX HC 
Reversed mutation result- 
ing from PCR oligomer 
Mute 4 
Mute 5 GAATATCCATGTGGAAAAATACCTACCTATTCTAG X 
7-4 
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blot  analysis were performed as described (24). 
Monoclonal Antibodies Used in Immunoradiometric Assays and 
Western Blot Analysis-The specificities of the  factor  IX monoclonal 
antibodies (MoAb) are as follows: MoAb A7, specificity is between 
amino acids 1 and 42; MoAb A l ,  amino acids 147-153; MoAb A5, 
amino  acids 180-310; MoAb FxC008, amino  acids 180-310 (10). The 
specificity of the  factor VI1 MoAb CDVII  resides within  amino acids 
1-50 of factor VII. The specificity for MoAb CIVII resides within 
amino acids 50-152 of factor VII. 
Iodination of Factor VII-Factor VIIa was iodinated with Na'*'I 
using IODOBEADS according to the manufacturer's instructions. 
The radiolabeled factor VIIa  was separated from  free Iz5I on a Seph- 
adex '2-25 (fine) column. The radiolabeled recombinant  factor VIIa 
had a specific activity of -1.0 pCi/pg and  retained  normal  clotting 
activity by a prothrombin  time assay. 
Binding Studies-Recombinant human tissue factor apoprotein 
(rTF) was provided to  us at a concentration of 0.1 mg/ml in 10 mM 
sodium phosphate, 150 mM NaCI, 0.9% octyl glucoside, pH 7.3. Just 
prior to use, the  rTF was diluted to a concentration of 0.5  pg/300 pl 
in  Western  blot  transfer buffer  composed of 20 mM Tris,  pH 7.5,  77 
mM glycine, and 20% methanol. The  rTF was then  dot  blotted on  a 
prewet Immobilon-P transfer membrane. The Immobilon-P mem- 
brane was  prewet  according to  the  manufacturer's  instructions.  The 
dot  blotting was  conducted  using a Minifold  I dot  blot  apparatus. 0.5 
pg of rTF in 300 pl of Western  transfer buffer  was  loaded into  each 
well and  blotted slowly under weak vacuum onto  the  Immobilon-P 
membrane. This was followed by an additional 2 ml/well of Western 
transfer buffer. The  apparatus was then  dismantled  and  the Immo- 
bilon membrane removed and allowed to  dry  at room temperature. 
The  rTF  dots were then excised  using a hole puncher.  Each individual 
membrane circle was  rewet  with methanol for 30 s followed by water 
for 1 min. Using a 48-well tissue  culture  plate,  the  rehydrated  rTF 
membrane circles were then placed into individual wells containing 
250 pl of blocking  solution. The blocking solution is 3% (w/v) nonfat 
dry milk in  phosphate-buffered  saline, pH 7.4. After  blocking  for 1 h 
at room temperature,  the blocking solution was removed and replaced 
with  the competitive binding mix. The competitive binding mix was 
composed of 5.0 nM I2'II recombinant factor VIIa plus increasing 
concentrations of recombinant competitors in 200 pl of blocking 
solution. The mixture plus the rTF circles were incubated on a 
rotating  table a t  25 rpm for 3 h. At the  end of this  incubation,  the 
rTF membranes were washed  rapidly 5 times  (total washing  time, -5 
min) with  washing  buffer  composed of 20 mM Tris-CI, pH 7.5, 100 
mM NaCI, 1 0  mM CaC12, 0.1% bovine serum albumin, and 0.05% 
Tween 20. The  first two washes were with I ml of washing buffer 
which was then immediately aspirated  with  no  incubation time. The 
latter  three washes were with 300 pl of washing solution for 1 min  on 
a rotating  table a t  100 rpm. When washing  was  complete, each rTF 
membrane circle was assessed for bound radioactivity in a LKB 
minigamma counter (model 1275). The  binding  data were evaluated 
and dissociation constants calculated using  the  nonlinear regression 
program  MK model (Biosoft). 
RESULTS 
Production  and Churacterization of Recombinant  Proteins- 
In  this  study,  eight  recombinant  proteins were generated. Six 
of the  eight  are chimeric proteins composed of portions of 
factors VI1 and IX. The  other two remaining  are wild-type 
factors VI1 and  IX (Fig. 1). The  proteins were produced in 
the  human embryo  kidney cell line 293 and  then  immunopu- 
rified  with Ca2+-dependent monoclonal  antibodies. The  puri- 
fied proteins were initially evaluated by SDS-PAGE followed 
by silver staining.  Recombinant  factor VI1 was activated to 
VIIa  during  the expression and purification.  Because of the 
complexity of the  different  activators needed, the  activation 
and  the biological activity of these  proteins will be  described 
separately. The mobility of the  eight  recombinants relative to 
the plasma factors VI1 and  IX were appropriate (data not 
shown). The recombinants were further characterized by 
Western  blot  analysis using  monoclonal antibodies  with rec- 
ognition  epitopes in  the  Gla/aromatic  stack region of factor 
VI1 and  IX,  the  activation  peptide of factor  IX,  and  the avy 
chain of factor IX (Fig. 2). These  characterizations  indicate 
that the set of eight recombinants possesses the expected 
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FIG. 1. Homologous exchanges between factors VI1 and IX. 
There  are  eight  recombinant proteins,  two wild type  and six chimeric. 
The protein  domains  are  as follows: signal  peptide (S); propeptide 
(P); y-carboxyglutamic acid (GLA);  aromatic stack (A); epidermal 
growth factor domains (EGFZ and EGF2); activation region (AR); 
and a catalytic region. The signal peptide and the propeptide are 
proteolytically removed during expression. Factor VI1 and  portions 
of factor VI1 are  in white, whereas factor  IX  and  portions of factor 
IX  are  in black. Within  the chimeras, the specific adjacent  amino acid 
residues  from factors VI1 and  IX  that comprise the exchange sites 
are indicated by numbers. The activation sites are represented as 
follows: A, VI1 activation site; A, IX  activation sites. 
A 
1 2  3 4 5 6 7 8 9 101112 1 2 3  4 5 6  7 6 9 1 0 1 1 1 2  ~- "." ~ .," . 
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FIG. 2. Nonreduced SDS-PAGE and Western  blot analysis 
of recombinant proteins. PanelA was probed  with antibody CDVII; 
panel R with antibody A7; panel C with antibody A l ;  panel D with 
FxC008. Lane designations: lane 1 ,  plasma factor  IX,  lane 2, plasma 
factor  IXa;  lane 3, recombinant  factor  IX, lane 4, plasma  factor VII; 
lane 5, plasma factor VIIa; lane 6, recombinant VIIa; lane 7, IX-A/ 
VII; lane 8, IX-EGF2/VII; lane 9, IX LC/VII HC; lane 10, VII-A/IX; 
lane 11, VII-EGFZ/IX  lane 12, VI1 LC/IX HC. 
antibody recognition  epitopes and is consistent with the  pro- 
teins depicted in Fig. 1. The  clotting activities of wild type 
recombinant  factors VI1 and  IX were normal. 
Tissue Factor Binding-Other studies have  shown that  rTF 
will specifically interact  with  factor VI1 (2, 7). rTF enhances 
catalytic efficiency of factor VIIa by 5000-fold, which is -9% 
of the  enhancement observed in  the presence of relipidated 
tissue  factor (2). In  order  to  evaluate  the tissue  factor/factor 
VI1 interaction we chose to utilize the observation that tissue 
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factor  and factor VI1 interact effectively and specifically in 
the absence of phospholipid. This capability allowed us to use 
purified components to study the interaction, thus eliminating 
the complicating features of nonspecific phospholipid binding 
in relipidated tissue factor assays or  internalization of ligand 
characteristic of cell binding assays. We examined the capa- 
bility of the six factor VII/IX recombinant chimeras and  the 
two wild-type protein factors VIIa and factor IX (Fig. 1) to 
bind to  rTF bound to  an Immobilon-P membrane. The initial 
experiments were to evaluate the specificity of binding of 
recombinant factor VIIa to  rTF bound to  an Immobilon-P 
membrane. This was demonstrated by incubating  lZ5I factor 
VIIa with Immobilon-P membrane circles with and without 
blctted rTF (see "Methods"). The amount of lZ5I factor VIIa 
bound to  the membrane in  the absence of rTF was <lo% of 
the amount bound in the presence of the blotted rTF. When 
EDTA was included in the washing solution, the amount of 
lz5I factor VIIa that remained bound to  the  rTF circles was 
identical to that which bound to  the circles in  the absence of 
rTF.  The binding of factor VIIa to  the blotted rTF circles 
approaches equilibrium at -3 h. The interaction appears 
saturable with half-maximal binding occurring at -30 nM. 
This value is comparable with that published by Ruf et al. (7) 
with solubilized tissue factor (-10 nM) or a recombinant 
mutant tissue factor (minus the transmembrane region) (-100 
nM). In an effort to generate relative binding affinities be- 
tween the recombinant proteins  and the bound rTF, compe- 
tition experiments were performed as described (see "Meth- 
ods''). The  data from these experiments clearly demonstrate 
that the recombinant proteins (wild type) VIIa, VI1 LC/IX 
HC, VII-EGFZ/IX, and IX-A/VII will compete with lZ5I factor 
VIIa for rTF, whereas factors IX,  IX LC/VII HC, IX-EGF2/ 
VII, and VII-A/IX show no competition out  to 1 PM (Fig. 3). 
The relative dissociation constants calculated from this  data 
are compiled in Table 11. 
Gla Analysis-Native factor VI1 possesses 10 Gla residues 
while factor IX  has 12. The Gla content of the recombinant 
proteins was evaluated by the method of Kuwada and  Katay- 
ama (25). This analysis revealed that most of the recombi- 
nants possess 70% (+) of their expected Gla content. The two 
exceptions, factors VI1 LC/IX HC and IX-A/VII, possess 47 
and 38%, respectively, of the theoretical Gla content  (Table 
11). The Gla content values are determined from the total 
number of Gla residues in  a fixed amount of protein. The 
minimum Gla content of a recombinant protein necessary for 
purification with the calcium-dependent antibodies A7 and 
CDVII is unknown. 
DISCUSSION 
Factor VI1 and Factor IX play a  central role in the proco- 
agulant aspect of human hemostasis. Their activity in blood 
coagulation requires that they interact specifically with a 
number of essential hemostatic proteins, from activating  pro- 
teases  and  inhibitors to cofactors and receptors. In  this report, 
we begin a study whose long-term goal is to determine what 
portions of factor VI1 and IX determine their respective 
specificities. In order to unravel these specific relationships, 
we chose to create  a family of chimeric proteins composed of 
homologous  regional exchanges between factors VI1 and  IX. 
This approach is based on the observation that functionally 
related proteins with amino acid sequence identity in the 
range of 40-50%, such as trypsin and chymotrypsin, share 
similar tertiary  structures.  Factors VI1 and  IX  are functionally 
related homologous proteins with amino acid sequence iden- 
tity of -44-45%. It is therefore likely that factors VI1 and  IX 
share a similar tertiary structure. Homologous exchanges 
l A  
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FIG. 3. Displacement  of '261-factor VIIa from rTF bound to 
Immobilon-P. Panel A,  factor IX (0), Factor VIIa (0); panel B, IX 
Lc/vII HC (A), VI1 LC/IX HC (A); panel C, IX-EGFB/VII (H), VII- 
EGFP/IX (13); panel D, IX-A/VII (Vi, VII-A/IX (+);panel  E, Factor 
VIIa (O), VI1 LC/IX HC (A), VII-EGF2/1X (O), IX-A/VII (0). 
between factors VI1 and IX are an attempt to preserve as 
nearly as possible the tertiary  structure of a native coagulation 
protease, while simultaneously segregating specificity. Our 
goal  was to generate chimeric proteins that would retain, lose, 
or acquire the functional characteristics of factors VI1 or IX, 
or both. 
In  this  report, we begin a  structure/function characteriza- 
tion of human factors VI1 and IX by utilizing a family of 
factor VII/IX chimeric proteins  to localize the tissue factor 
recognition determinant of human factor VII. There have 
been several studies that have attempted to define the struc- 
tural determinants on human factor VI1 that mediate its 
recognition of tissue factor (6-8). Two of these  reports have 
implicated the factor VI1 Gla domain (6,7) as being important 
for the interaction.  In one case ( 6 ) ,  Gla-domainless factor VI1 
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TABLE I1 
Gla analysis and calculated K d  values for the recombinant proteins 
The number of experimental points  per competitor ranged from 20 
to 60. The dash indicates that no competition with the recombinant 
was observed. ND, not done. 
Ligands/controls Gla" Kd values 
nM 
Plasma factor X 10.2 f 0.05 ND 
Plasma factor IX 10.9 f 0.1 ND 
Recombinant factor IX ND 
Recombinant factor VIIa 7.15 f 0.05 21 -+ 8 
IX LC/VII HC 10.75 f 0.05 





IX-A/VII 4.65 f 0.05 222 -+ 22 
VII-A/IX 8.3 - 
4.75 f 0.05 79 -+ 7.6 
7.65 f 0.15 21 -+ 4.5 
8.8 - 
Values represent the  total number of Gla residues per molecule. 
was unable to interact at all with constitutively expressed 
tissue factor on a human bladder carcinoma cell line (582). In 
contrast, in the other study, Gla-domainless factor VI1 was 
shown to bind to solubilized tissue factor and  a recombinant 
mutant tissue factor (minus the trans-membrane region) with 
Kd values of 112 and 120 nM, respectively (7). In a  third  study 
(8)) a peptide corresponding to amino acids 195-206 of the 
factor VI1 heavy chain was shown to inhibit factor VII/tissue 
factor interaction with a K ,  of 1-2 mM. The  data described in 
this report indicate the following. 1) The tissue factor/VIIa 
interaction is Ca2+-dependent, in that  the binding of factor 
VIIa to  rTF is completely reversible in  the presence of EDTA. 
This Ca2+ dependence is consistent with the observations of 
others (6, 7). 2) The interaction of factor VIIa with tissue 
factor is predominantly mediated by the EGF domains. 
The competition experiments (Fig. 3) with factors IX LC/ 
VI1  HC and IX-EGF2/VII indicate that  the heavy chain of 
factor VIIa does not  contribute  any high affinity specificity 
for tissue factor binding. The high affinity interaction is 
clearly mediated by the light chain  as evidenced by the binding 
constants of wild-type factor VIIa (21 nM) and factor VII- 
EGF2/IX (21 nM). It also appears that  the Gla domain of 
factor VI1 in and of itself does not mediate the interaction. 
Otherwise, one would have expected VII-A/IX to have dis- 
played competition. We cannot exclude the Gla  region from 
any participation due to  the binding constants of  VI1 LC/IX 
HC (80 nM) and IX-A/VII (220 nM). The extensive undercar- 
boxylation of these chimeras excludes any definitive interpre- 
tation of these relative binding constants. The lower affinity 
for tissue factor with the undercarboxylated chimeras may 
suggest that  the low affinity Ca2+ binding ordinarily present 
in  the Gla  region has been perturbed. This would  be consistent 
with the  demonstration by  Ruf et al. (7) that  the low affinity 
calcium-binding sites of the VI1 Gla domain must be saturated 
for tight binding to tissue factor. In order to address this 
point of either direct or indirect participation by the factor 
VII(a) Gla domain in tissue factor specificity, we are presently 
attempting to purify fully carboxylated versions of these chi- 
meras. One possible scenario is that a Ca2+-dependent con- 
formation of the Gla domain is providing some degree of 
structural integrity to the  EGF domains, meaning that  the 
role of the Gla domain may  be a  structural role and  not one 
of direct specificity. It is clear that  the majority of the binding 
affinity of factor VII(a) for rTF is within the  EGF domains. 
Whether EGF1, EGF2, or both domains are required to me- 
diate this interaction will  be the subject of further investiga- 
tion. 
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